- Home
- RCS vs TMCI Comparison
RCS vs TMCI Comparison
Compare RCS & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCS
- TMCI
- Stock Information
- Founded
- RCS 1994
- TMCI 2014
- Country
- RCS United States
- TMCI United States
- Employees
- RCS N/A
- TMCI N/A
- Industry
- RCS Investment Managers
- TMCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- RCS Finance
- TMCI Health Care
- Exchange
- RCS Nasdaq
- TMCI Nasdaq
- Market Cap
- RCS 358.4M
- TMCI 401.8M
- IPO Year
- RCS N/A
- TMCI 2021
- Fundamental
- Price
- RCS $7.14
- TMCI $6.48
- Analyst Decision
- RCS
- TMCI Hold
- Analyst Count
- RCS 0
- TMCI 5
- Target Price
- RCS N/A
- TMCI $8.40
- AVG Volume (30 Days)
- RCS 141.1K
- TMCI 208.5K
- Earning Date
- RCS 01-01-0001
- TMCI 11-06-2025
- Dividend Yield
- RCS 10.12%
- TMCI N/A
- EPS Growth
- RCS N/A
- TMCI N/A
- EPS
- RCS N/A
- TMCI N/A
- Revenue
- RCS N/A
- TMCI $213,751,000.00
- Revenue This Year
- RCS N/A
- TMCI $10.63
- Revenue Next Year
- RCS N/A
- TMCI $9.43
- P/E Ratio
- RCS N/A
- TMCI N/A
- Revenue Growth
- RCS N/A
- TMCI 7.67
- 52 Week Low
- RCS $4.51
- TMCI $4.70
- 52 Week High
- RCS $6.31
- TMCI $10.79
- Technical
- Relative Strength Index (RSI)
- RCS 40.92
- TMCI 46.79
- Support Level
- RCS $7.53
- TMCI $6.23
- Resistance Level
- RCS $7.30
- TMCI $6.65
- Average True Range (ATR)
- RCS 0.17
- TMCI 0.27
- MACD
- RCS -0.01
- TMCI -0.01
- Stochastic Oscillator
- RCS 26.08
- TMCI 39.14
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About TMCI Treace Medical Concepts Inc.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.